CD19 and hematologic disorder: Predominantly, CAR T cell therapies exert remarkable clinical results in certain hematological malignancies, like B cell leukemia and lymphoma, using, e.g., CD19 as target antigen, which was the first CAR T cell therapy approved by the US Food and Drug Administration (FDA) in 2017 (146).